Abbonarsi

Efficacy and safety of single-session argon plasma coagulation in the management of chronic radiation proctitis - 24/08/11

Doi : 10.1016/j.gie.2010.01.065 
Michael P. Swan, MBBS, FRACP , Greg T.C. Moore, MBBS, PhD, FRACP, William Sievert, MD, FRACP, David A. Devonshire, MBBS, FRACP
Endoscopy Unit, Monash Medical Centre, Clayton, Victoria, Australia. 

Reprint requests: Michael P. Swan, MBBS, FRACP, c/o Department of Gastroenterology, Monash Medical Centre, Clayton Road, Clayton, Victoria, Australia 3168

Riassunto

Background

Chronic radiation proctitis (CRP) manifests as rectal bleeding 12 to 24 months after pelvic radiotherapy. No criterion standard of treatment has been established, although argon plasma coagulation (APC) has increasingly become the treatment of choice. Previous studies have applied APC over multiple sessions, necessitating increased numbers of treatments.

Objective

To assess the safety and efficacy of large-volume APC application in the treatment of CRP with the intention of a single-session treatment protocol.

Design

Prospective study.

Setting

Tertiary referral hospital.

Patients

Over an 8-year period, consecutive patients with CRP with rectal bleeding were prospectively enrolled.

Intervention

Large-volume APC application to affected rectal mucosa.

Main Outcome Measurements

Number of treatments, bleeding scores, complications.

Results

Fifty patients (mean age 72.1 years; range 51-87 years) were treated; 45 were men (prostate cancer). The mean period between radiotherapy and initial APC treatment was 23 months (range 4-140 months). Seventeen (34%) patients had grade A endoscopic severity, 23 (46%) grade B, and 10 (20%) grade C. Other therapies failed in 16 (32%) patients. The mean number of treatments was 1.36 (range 1-3) with a mean follow-up of 20.6 months (range 6-48 months). Sixty-eight percent of patients were successfully treated after 1 session and 96% after 2 sessions. Bleeding scores improved in all patients (P < .001). Seventeen (34%) patients experienced short-term, self-limiting complications; 1 (2%) patient experienced a long-term complication.

Limitations

Nonrandomized study.

Conclusions

Large-volume APC treatment was successful in the treatment of CRP, including those in whom other therapies had previously failed, and resulted in a decreased number of treatments compared with other published studies. The benefits were offset by an increased incidence of short-term complications but no increase in long-term complications.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : APC, CRP


Mappa


 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.


© 2010  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 72 - N° 1

P. 150-154 - luglio 2010 Ritorno al numero
Articolo precedente Articolo precedente
  • Endoscopic submucosal dissection for treatment of rectal carcinoid tumors
  • Hye-Won Park, Jeong-Sik Byeon, Young Soo Park, Dong-Hoon Yang, Soon Man Yoon, Kyung-Jo Kim, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jin-Ho Kim
| Articolo seguente Articolo seguente
  • Efficacy of a prototype endoscope with two deflecting working channels for endoscopic submucosal dissection: a prospective, comparative, ex vivo study
  • Suck-Ho Lee, Mark A. Gromski, Alexandre Derevianko, Daniel B. Jones, Douglas K. Pleskow, Mandeep Sawhney, Ram Chuttani, Kai Matthes

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.